Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Will Use One Distributor To Ensure Patient Access For Orencia Launch

Executive Summary

Bristol-Myers Squibb is launching its rheumatoid arthritis treatment Orencia (abatacept) through a sole distributor to ensure patient access while the firm works to expand its manufacturing capacity
Advertisement

Related Content

Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Bristol Gears Up For Orencia Launch With Creation Of Immunoscience Unit
Bristol Gears Up For Orencia Launch With Creation Of Immunoscience Unit
Roche Fuzeon Approval Presents Challenges Of Reimbursement, Supply
Amgen/Wyeth Enbrel Supplies Replenished With Rhode Island Plant Approval
Advertisement
UsernamePublicRestriction

Register

PS046696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel